Medicare Enrolled
Dr. Bahareh Bahadini, MD
Medical Oncology · Thousand Oaks, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bahadini from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bahadini?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bahadini
Dr. Bahareh Bahadini is a medical oncology specialist in Thousand Oaks, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Bahadini performed 92,028 Medicare services across 1,441 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bahadini received a total of $2,949 from 32 pharmaceutical and/or device companies across 143 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bahadini is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in CA
$2,949 industry payments
Medicare Practice Summary
Medicare Utilization ↗92,028
Medicare services
Top 6% in CA for medical oncology
1,441
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,601 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
18,180 | $0 | $1 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
18,000 | $1 | $4 |
| Denosumab injection (Prolia/Xgeva) | 15,420 | $18 | $82 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
12,200 | $2 | $11 |
| Anti-nausea injection (aprepitant) | 9,880 | $1 | $6 |
| Pembrolizumab injection (Keytruda) | 4,800 | $43 | $192 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
4,062 | $36 | $160 |
| Anti-nausea injection (ondansetron/Zofran) | 2,160 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,578 | $0 | $0 |
| Injection, fulvestrant, 25 mg | 1,050 | $8 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
880 | $102 | $481 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
488 | $150 | $672 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
464 | $14 | $93 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
372 | $82 | $368 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
368 | $12 | $81 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
329 | $120 | $606 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
185 | $18 | $88 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
159 | $31 | $134 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
149 | $25 | $109 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
143 | $67 | $292 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
124 | $59 | $269 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
123 | $26 | $147 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
110 | $25 | $134 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
107 | $1 | $4 |
| New patient office visit, complex (60-74 min) | 87 | $183 | $821 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
66 | $1 | $6 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
56 | $59 | $295 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
52 | $1 | $21 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
48 | $69 | $306 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
46 | $24 | $103 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
44 | $11 | $69 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 44 | $14 | $62 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
41 | $84 | $394 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
40 | $50 | $247 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
37 | $29 | $220 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
37 | $27 | $214 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
36 | $61 | $341 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
33 | $2 | $9 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
30 | $16 | $81 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
24.9% high complexity
73.0% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,949
Total received (2018-2024)
Avg $421/year across 7 years
Bottom 44% in CA for medical oncology
32
Companies
143
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,502 (84.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$447 (15.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$88
2023
$13
2022
$112
2021
$183
2020
$350
2019
$1,298
2018
$904
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$88
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$444
E.R. Squibb & Sons, L.L.C.
$404
Genentech USA, Inc.
$254
Amgen Inc.
$253
AstraZeneca Pharmaceuticals LP
$183
Merck Sharp & Dohme Corporation
$158
Seattle Genetics, Inc.
$135
Veran Medical Technologies, Inc.
$92
Boehringer Ingelheim Pharmaceuticals, Inc.
$90
GENZYME CORPORATION
$88
Gilead Sciences, Inc.
$86
Celgene Corporation
$73
GlaxoSmithKline, LLC.
$73
EMD Serono, Inc.
$69
Incyte Corporation
$67
Astellas Pharma US Inc
$67
Novartis Pharmaceuticals Corporation
$58
Exelixis Inc.
$43
Seagen Inc.
$36
Puma Biotechnology, Inc.
$36
Janssen Biotech, Inc.
$28
TESARO, Inc.
$28
Alexion Pharmaceuticals, Inc.
$23
Lexicon Pharmaceuticals, Inc.
$23
Bayer HealthCare Pharmaceuticals Inc.
$22
Daiichi Sankyo Inc.
$19
Pharmacyclics LLC, An AbbVie Company
$19
INSYS Therapeutics Inc
$18
Eisai Inc.
$17
EISAI INC.
$15
Lilly USA, LLC
$14
Janssen Pharmaceuticals, Inc
$13
Top 3 companies account for 37.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Alecensa · Aranesp · Avastin · BAVENCIO · BOSULIF · Bavencio · CABLIVI · Cabometyx · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · GILOTRIF · Halaven · IBRANCE · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LORBRENA · Lenvima · MVASI · Nerlynx · Neulasta · OPDIVO · PIQRAY · Pomalyst · RYBREVANT · Revlimid · SUTENT · SYNDROS · Spin · Stivarga · TAGRISSO · TALZENNA · TECENTRIQ · TUMOR LYSIS SYNDROME - DISEASE · Ultomiris · VERZENIO · XALKORI · XTANDI · Xermelo · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
17
Per 100K population
2.0
County median income
$107,327
Nearest hospital
LOS ROBLES HOSPITAL & MEDICAL CENTER
5.3 mi
5.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bahadini is a mixed practice specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bahadini experienced with filgrastim injection (zarxio) for white blood cells?
Based on Medicare claims data, Dr. Bahadini performed 18,180 filgrastim injection (zarxio) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bahadini receive payments from pharmaceutical companies?
Yes. Dr. Bahadini received a total of $2,949 from 32 companies across 143 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bahadini's costs compare to other medical oncologists in Thousand Oaks?
Dr. Bahadini's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bahadini) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Thousand Oaks
Browse medical oncologists in Thousand Oaks ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology